Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas

Zhang,Fan; Chu,Jinjin; Wang,Fan

doi:10.3892/ol.2017.6281

Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas

Authors:
- Fan Zhang
- Jinjin Chu
- Fan Wang
View Affiliations

Affiliations: Department of Radiotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: May 31, 2017 https://doi.org/10.3892/ol.2017.6281
Pages: 1303-1308
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine cyclooxygenase 2 (COX-2) and survivin expression levels in glioma tissues, and to investigate their association with clinicopathological factors and patient survival. Immunohistochemistry was performed to evaluate COX‑2 and survivin expression levels in paraffin‑embedded surgically resected tissues from 70 patients with glioma and 7 individuals with normal brain tissues. The association between COX‑2 and survivin expression levels and clinicopathological features was investigated using the χ2 test, and the survival time was analyzed using the Kaplan Meier method with log‑rank test. COX‑2 and survivin were overexpressed in glioma tissues, and higher expression levels were observed in glioma tissues of histological grades III‑IV compared with those in grade I‑II tumor tissues (P<0.05); however, the expression levels were not associated with gender, age, tumor size or location (P>0.05). There was a significant positive association between the expression levels of COX‑2 and survivin in the glioma tissues. Additionally, COX‑2 and survivin expression levels were significantly negatively correlated with the rate of survival. In conclusion, COX‑2 and survivin expression is positively associated with the pathological grade of a glioma and may contribute to glioma tumorigenesis. Therefore, COX‑2 and survivin may be sensitive predictors of a negative clinical prognosis for patients with glioma.

View Figures

View References

1	Holland EC: Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA. 97:pp. 6242–6244. 2000; View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Pomeroy SL and Cairncross JG: Focus on central nervous system neoplasia. Cancer Cell. 1:125–128. 2002. View Article : Google Scholar : PubMed/NCBI
3	Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB and Berens ME: Molecular targets of glioma invasion. Cell Mol Life Sci. 64:458–78. 2007. View Article : Google Scholar : PubMed/NCBI
4	Omay SB and Vogelbaum MA: Current concepts and newer developments in the treatment of malignant gliomas. Indian J Cancer. 46:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lima FR, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca AC, Garcia C, Romão L, Brito J, Holanda-Afonso R, et al: Glioblastoma: Therapeutic challenges, what lies ahead. Biochim Biophys Acta. 1826:338–349. 2012.PubMed/NCBI
6	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ke HL, Tu HP, Lin HH, Chai CY, Chang LL, Li WM, Li CC, Lee YC, Yeh HC, Wu WJ and Bau DT: Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer. Anticancer Res. 32:4111–4116. 2012.PubMed/NCBI
8	Cebola I and Peinado MA: Epigenetic deregulation of the COX pathway in cancer. Prog Lipid Res. 51:301–313. 2012. View Article : Google Scholar : PubMed/NCBI
9	Rödel F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T, Fulda S and Rödel C: The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition. Curr Med Chem. 18:191–199. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kanwar JR, Kamalapuram SK and Kanwar RK: Targeting survivin in cancer: Patent review. Expert Opin Ther Pat. 20:1723–1737. 2010. View Article : Google Scholar : PubMed/NCBI
11	Chen XQ, Yang S, Li ZY, Lu HS, Kang MQ and Lin TY: Effects and mechanism of downregulation of survivin expression by RNA interference on proliferationand apoptosis of lung cancer cells. Mol Med Rep. 5:917–922. 2012.PubMed/NCBI
12	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–1099. 2007. View Article : Google Scholar : PubMed/NCBI
13	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
14	Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885. 2005. View Article : Google Scholar : PubMed/NCBI
15	Trifan OC and Hla T: Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 7:207–222. 2003. View Article : Google Scholar : PubMed/NCBI
16	Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI
17	Grösch S, Maier TJ, Schiffmann S and Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 98:736–47. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kim YM, Shin YK, Jun HJ, Rha SY and Pyo H: Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor. Radiat Res. 52:752–765. 2011. View Article : Google Scholar
19	Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M and Thill M: Impact of cyclooxygenase-2 in breast cancer. Anticancer Res. 31:4359–4367. 2011.PubMed/NCBI
20	Moreira L and Castells A: Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets. 12:1888–1894. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schrör K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:198–204. 1999.PubMed/NCBI
22	Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE 2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
23	Temel SG and Kahveci Z: Cyclooxygenase-2 expression in astrocytes and microgliain human oligodendroglioma and astrocytoma. J Mol Histol. 40:369–377. 2009. View Article : Google Scholar : PubMed/NCBI
24	El-Sayed M and Taha MM: Immunohistochemical expression of cycloxygenase-2 in astrocytoma: Correlation with Angiogenesis, tumor progression and survival. Turk Neurosurg. 21:27–35. 2011.PubMed/NCBI
25	Altieri DC: Targeting survivin in cancer. Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI
26	Liu W, Zhu F, Jiang Y, Sun D, Yang B and Yan H: SiRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellularcarcinoma cells. Oncol Rep. 29:1183–1188. 2013.PubMed/NCBI
27	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
28	Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA and Conti E: Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell. 131:271–285. 2007. View Article : Google Scholar : PubMed/NCBI
29	Altieri DC: Survivin-The inconvenient IAP. Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
30	Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Suzuki Y, Itoh J, Itoh H, Ishiuchi S, Sakurai H, et al: Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol. 91:353–358. 2009. View Article : Google Scholar : PubMed/NCBI
31	Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Oncol. 20:1063–1068. 2002.
32	Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A and Ohta S: Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci. 15:1198–1203. 2008. View Article : Google Scholar : PubMed/NCBI
33	Mehar A, Macanas-Pirard P, Mizokami A, Takahashi Y, Kass GE and Coley HM: The effects of cyclooxygenase-2 expression in prostate cancer cells: Modulation of response to cytotoxic agents. J Pharmocol Exp Ther. 324:1181–1187. 2008. View Article : Google Scholar
34	Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, Athanassiadou AM, Tsipis A and Patsouris E: The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract. 204:241–249. 2008. View Article : Google Scholar : PubMed/NCBI
35	Erkanli S, Bolat F, Kayaselcuk F, Demirhan B and Kuscu E: COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol. 104:320–325. 2007. View Article : Google Scholar : PubMed/NCBI
36	Ren Z, Zhang LZ and Wang RZ: Effect of celecoxib on proliferation, apoptosis and Survivin expression in human glioma cell line U251. Chin J Can. 29:294–299. 2010. View Article : Google Scholar
37	Schetter AJ, Heegaard NH and Harris CC: Inflammation and cancer: Interweaving micro RNA, free radical, cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010. View Article : Google Scholar : PubMed/NCBI
38	Rödel F, Frey B, Leitmann W, Capalbo G, Weiss C and Rödel C: Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissues culture and murine xenograft models. Int J Radiat oncol Biol Phys. 71:247–255. 2008. View Article : Google Scholar : PubMed/NCBI